172
Participants
Start Date
May 20, 2021
Primary Completion Date
January 1, 2027
Study Completion Date
January 1, 2028
Cytarabine
Intravenous infusion
Idarubicin
Intravenous infusion
Daunorubicin
Intravenous infusion
Liposomal daunorubicin and cytarabine
Intravenous infusion
Venetoclax
Orally by mouth
Azacitidine
Intravenous infusion
RECRUITING
University of Pennsylvania, Philadelphia
RECRUITING
Atrium Health Levine Cancer Institute, Charlotte
RECRUITING
Ohio State University Medical Center, Columbus
RECRUITING
City of Hope, Duarte
RECRUITING
Stanford Cancer Center, Palo Alto
RECRUITING
University of California - Davis, Sacramento
RECRUITING
Massachusetts General Hospital Cancer Center, Boston
RECRUITING
Beth Israel Deaconess Medical Center, Boston
RECRUITING
Dana-Farber Cancer Institute, Boston
Collaborators (1)
AbbVie
INDUSTRY
Massachusetts General Hospital
OTHER